Skip to main content

Next Generation 
Therapies for
Neurodegenerative
Diseases

Mission

At Galimedix, we are working to improve the lives of millions of patients worldwide by developing game-changing drugs to treat major neurodegenerative diseases where amyloid beta plays a role and where better treatments are urgently needed, including dry AMD, glaucoma and Alzheimer’s disease, our initial areas of focus.

Our lead candidate, GAL-101, is currently in Phase 2 clinical testing for the treatment of dry AMD.

Explore

Galimedix’s approach is to block a key step in the neurodegenerative process with a highly specific and well tolerated compound without impacting normal neuronal function

Treating Neurodegeneration of the Eye and Brain

We are developing small molecules with a unique mechanism of action that allows us to address the root cause and alter the course of disease. GAL-101, Galimedix’s lead clinical candidate, is in Phase 2 testing for the treatment of dry age-related macular degeneration (dry AMD). The compound is also being developed for the treatment of glaucoma and Alzheimer’s disease.

Our products

Designed to be Patient Friendly

Our product candidates are designed to be delivered via convenient administration routes – as eye drops or orally as tablets – easy for the patient and caregiver and less burdensome to the healthcare system. More importantly, they are designed to be well tolerated with fewer side effects than current treatment options.

Our team

Meet the people behind our pioneering science

News

Progress in clinical development for Alzheimer’s and other indications: Galimedix Therapeutics successfully completes Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modulator

September 12, 2025
Our Science

Learn more about our novel approach

We are developing potentially disruptive technology with a unique mechanism of action that enables us to tackle major neurodegenerative diseases at the root